Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). (Q54361083)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

toll-like receptor

0 references

1 reference

based on heuristic

inferred from title

author name string

David N Taylor

1

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

John J Treanor

2

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

Cynthia Strout

3

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

Casey Johnson

4

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

Theresa Fitzgerald

5

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

Uma Kavita

6

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

Karen Ozer

7

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

Lynda Tussey

8

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

Alan Shaw

9

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

language of work or name

0 references

publication date

17 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

number of pages

6

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

29

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

31

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

4897-4902

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

Mortality associated with influenza and respiratory syncytial virus in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

The annual impact of seasonal influenza in the US: Measuring disease burden and costs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

The imperative of influenza vaccines for elderly individuals-an evolving story

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

Mortality benefits of influenza vaccination in elderly people: an ongoing controversy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

The number and location of glycans on influenza hemagglutinin determine folding and association with calnexin and calreticulin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

Importance of hemagglutinin glycosylation for the biological functions of influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

Toll-dependent selection of microbial antigens for presentation by dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

Regulation of phagosome maturation by signals from toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

Antibody response to influenza vaccination in the elderly: a quantitative review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.001

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.05.001

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/21596084

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54361083&oldid=1775334818"